Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys®)180 μg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B

NCT01524679 is registered in ClinicalTrials.gov with Johannes Gutenberg University Mainz as lead sponsor.

NCT NCT01524679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01524679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys®)180 μg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B
Lead sponsor
Johannes Gutenberg University Mainz
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
August 28, 2017
Enrollment
170 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b